Goto content

Leishrisk, Bridging Research and Leishmanianis Control

Leishrisk, Bridging Research and Leishmanianis Control

Kaladrug-R  publications

 


| introduction | overview workpackages | Kaladrug-R SOPs | agenda | publications | contacts |


 

 

Kaladrug-R reports

NEW Workshop 'New tools for monitoring drug-resistance and treatment response in visceral leishmaniasis in the Indian subcontinent', Godavari Village Resort, Kathmandu, September 26th 2012 - ABSTRACT BOOK - download PDF

NEW Workshop 'Monitoring of clinical outcomes of kala azar in the heath system & surveillance of drug resistance', Faridabad, January 27th 2012 - CONCLUSIONS - download PDF

NEW Workshop 'Monitoring of clinical outcomes of kala azar in the heath system & surveillance of drug resistance', Faridabad, January 27th 2012 - AGENDA and PRESENTATIONS - download PDF

Project mid-term project publishable summary - download PDF

Project mid-term presentation Kaladrug-R coordinator Prof. Dr. JC Dujardin at FP7 symposium for neglected tropical diseases - download PDF

 Project mid-term poster presentations Kaladrug-R consortium at FP7 symposium for neglected tropical diseases listed below:

1. Drug susceptibility of Indian field isolates of L. donovani and development of experimental resistance towards Miltefosine and Paromomycin by Bhandari et al. - download PDF abstract - download PDF poster
2. Microsatellite typing of Leishmania donovani from the Indian subcontinent reveals homogeneous population structure by Stark et al. - download PDF abstract - download PDF poster
3. How does antimonial resistance affect the survival skills of Leishmania donovani? by Vanaerschot et al. - download PDF abstract - download PDF poster
4. Modelling Visceral Leishmaniasis Transmission and Control by Stauch et al. - download PDF abstract - download PDF poster
5. Challenges for the implementation of new tools to monitor treatment outcome in Miltefosine-treated Kala-azar patients in India and Nepal by Ostyn et al. - download PDF abstract - download PDF poster
6. Molecular and biochemical characterization of resistant Leishmania donovani isolates by Mukhopadhyay et al. - download PDF abstract - download PDF poster
7. Experimental Induction of Paromomycin resistance in an antimony resistant Nepalese strain of L. donovani by Inocencio et al. - download PDF abstract - download PDF poster
8. Treatment of Indian visceral leishmaniasis with miltefosine - 10 Years Later by Prajapati et al. - download PDF abstract - download PDF poster
9. The utility and efficacy of miltefosine as A 1st line therapy for Kala-Azar in Nepal by Bhattarai et al. - download PDF abstract - download PDF poster
10. Inherent paromomycin susceptibility and induction of resistance of SSG-sensitive and SSG-resistant Nepalese Leishmania donovani strains by Longchamp et al. - download PDF abstract - download PDF poster
11. Natural susceptibility of Leishmania donovani isolates from Indian subcontinent towards Miltefosine and impact of SSG resistance background on development of Miltefosine resistance by Kulshrestha et al. - download PDF abstract - download PDF poster
12. The genome of Leishmania donovani from clinically isolated parasites in India and Nepal by Imamura et al. - download PDF abstract - download PDF poster
13. The dynamics of population genomic variation in Leishmania donovani clinical strains by Downing et al. - download PDF poster

  

Peer-reviewed research papers

Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain. (Rai K, Cuypers B, Bhattarai NR, Uranw S, Berg M, Ostyn B, Dujardin JC, Rijal S, Vanaerschot M. MBio 2013) - pubmed citation

Metabolic adaptations of Leishmania donovani in relation to differentiation, drug resistance, and drug pressure. (Berg M, Vanaerschot M, Jankevics A, Cuypers B, Maes I, Mukherjee S, Khanal B, Rijal S, Roy S, Opperdoes F, Breitling R, Dujardin JC. Mol Microbiol 2013) - pubmed citation

Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1. (Mukherjee B, Mukhopadhyay R, Bannerjee B, Chowdhury S, Mukherjee S, Naskar K, Allam US, Chakravortty D, Sundar S, Dujardin JC, Roy S. Proc Natl Acad Sci U. S. A 2013) - press release (The Telegraph India) -  pubmed citation

Adherence to miltefosine treatment for visceral leishmaniasis under routine conditions in Nepal. (Uranw S, Ostyn B, Hasker E, Dujardin B, Dujardin JC, Rijal S, Boelaert M. Trop Med Int Health 2013) - pubmed citation

Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani. (Kulshrestha A, Bhandari V, Mukhopadhyay R, Ramesh V, Sundar S, Maes L, Dujardin JC, Roy S, Salotra P. Parasitol Res 2013) - pubmed citation

Treatment of visceral leishmaniasis: model-based analysis on the spread of antimony-resistant L. donovani in Bihar, India. (Stauch A, Duerr HP, Dujardin JC, Vanaerschot M, Sundar S, Eichner M. Plos Negl Trop Dis 2012) - pubmed citation 

Imipramine is an orally active drug against both antimony sensitive and resistant Leishmania donovani clinical isolates in experimental conditions. (Mukherjee S, Mukherjee B, Mukhopadhyay R, Naskar K, Sundar S, Dujardin JC, Das AK, Roy S. Plos Negl Trop Dis 2012) - pubmed citation 

Genome-wide SNP and microsatellite variation illuminate population-level epidemiology in the Leishmania donovani species complex (Downing T, Stark O, Decuypere S, de Doncker S, Dujardin JC, Imamura H, Maes I, Rijal S, Sanders M, Sundar S, Vanaerschot M, Berriman M, Schönian G. Infect Genet Evol 2012) - pubmed citation

Role of oxidative stress and apoptosis in the cellular response of murine macrophages upon Leishmania infection.  (Deschacht M, Van Assche T, Hendrickx S, Bult H, Maes L, Cos P; Parasitology 2012) - pubmed citation

Metabolomics systems biology of protozoan parasites. (Breitling R, Bakker B, Barrett, M, Decuypere S, Dujardin JC; Genetics Meets Metabolomics: from experiment to systems biology 2012) - in press  

Genetic markers or SSG-resistance in Leishmania donovani and SSG-treatment failure in visceral leishmaniasis patients in the Indian subcontinent. (Vanaerschot M, Decuypere S, Downing T, Imamura H, Stark O, De Doncker S, Roy S, Maes L, Schönian G, Berriman M, Chappuis F, Dujardin JC, Sundar S, Rijal S; CID 2012) - pubmed citation

Molecular mechanisms of drug resistance in natural Leishmania populations vary with genetic background. (Decuypere S, Vanaerschot M, Brunker K, Imamura H, Müller S, Rijal S, Dujardin JC, Coombs GH; PLoS Negl Trop Dis 2012) - pubmed citation 

Efficacy of Miltefosine in the Treatment of Indian Visceral Leishmaniasis after a decade of use. (Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, Ostyn B, Boelaert M, Dujardin JC, Chakravarty J; CID 2012) - pubmed citation 

Epidemiology of leishmaniasis in the time of drug resistance. (Dujardin JC & Decuypere S; In: Drug Resistance in Leishmania Parasites. Consequences, Molecular Mechanism and Possible Treatments Edited by Alicia Ponte-Sucre, Maritza Padron-Nieves and Emilia Diaz. Spinger-Verlag, 2012) - in press

Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on selection protocol. (Hendrickx S, Inocêncio da Luz RA, Bhandari V, Lonchamp J, Salotra P, Carter K, Sundar S, Rijal S, Dujardin JC, Cos P, Maes L; PLoS NTD 2012) - pubmed citation 

Drug Susceptibility in Leishmania Isolates following Miltefosine Treatment in cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis. (Bhandari V, Kulshrestha A, Deep DK, Stark O, Prajapati VK, Ramesh V, Sundar S, Schonian G, Dujardin JC and Salotra P; PLoS NTD 2012) - pubmed citation

Molecular mechanisms of drug resistance in natural Leishmania populations vary with genetic background. (Decuypere S, Vanaerschot M, Brunker K, Imamura H, Müller S, Khanal B, Rijal S, Dujardin JC, Coombs GH; PLoS NTD 2012) - pubmed citation

Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control. (Stauch A, Sarkar RR, Picado A, Ostyn B, Sundar S, Rijal S, Boelaert M, Dujardin JC, Duerr HP; PLoS NTD 2011) - pubmed citation

Antimonial resistance in Leishmania donovani is associated with increased in vivo parasite burden. (Vanaerschot M, De Doncker S, Rijal S, Maes L, Dujardin JC, Decuypere S; PLoS One 2011) - pubmed citation

Increased metacyclogenesis rate among antimony-resistant Leishmania donovani clinical lines. (Ouakad M, Vanaerschot M, Rijal S, Sundar S, Speybrouck N, Kestens L, Boel L, De Doncker S, Maes I, Decuypere S, Dujardin JC; Parasitology 2011) - pubmed citation

Characterisation of antimony resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells. (Mukhopadhyay R, Mukherjee S, Mukherjee B, Naskar K, Mandal D, Decuypere S, Ostyn B, Prajapati VK, Sundar S, Dujardin JC, Roy S; Int J Parasitol 2011) - pubmed citation

Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into the evolution and mechanisms of drug resistance. (Downing T, Imamura H, Decuypere S, Clark TG, Coombs GH, Cotton JA, Hilley JD, de Doncker S, Maes I, Mottram J, Quail MA, Rijal S, Sanders M, Schönian G, Stark O, Sundar S, Vanaerschot M, Hertz-Fowler C, Dujardin JC, Berriman M; Genome Res 2011) - pubmed citation

Chromosome and gene copy number variation allow major structural change between species and strains of Leishmania. (Rogers MB, Hilley JD, Dickens NJ, Wilkes J, Bates P, Depledge DP, Harris D, Her Y, Herzyk P, Imamura H, Otto TD, Saad W, Seeger K, Dujardin JC, Berriman M, Smith DF, Hertz-Fowler C, Mottram JC; Genome Res 2011) - pubmed citation

Visceral leishmaniasis in the Indian subcontinent: modeling epidemiology and control. (Stauch A, Sarkar RR, Picado A, Ostyn B, Sundar S, Rijal S, Boelaert M, Dujardin JC, Duerr HP; PLoS Negl Trop Dis 2011) - pubmed citation

Genome-wide SNP and microsatellite variation unravel population-level Leishmania donovani species complex epidemiology. (Downing T, Stark O, Decuypere S, de Doncker S, Dujardin JC, Imamura H, Maes I, Rijal S, Sanders M, Sundar S, Vanaerschot M, Berriman M, Schönian G; Infect Genet Evol 2011) - pubmed citation


Monitoring drug effectiveness in kala-azar in Bihar, India: cost and feasibility of periodic random surveys vs. a health service-based reporting system. (Malaviya P, Singh RP, Singh SP, Hasker E, Ostyn B, Shankar R, Boelaert M, Sundar S; Trop Med Int Health 2011) - pubmed citation

Management of visceral leishmaniasis in rural primary health services in Bihar, India. (Hasker E, Singh SP, Malaviya P, Singh RP, Shankar R, Boelaert M, Sundar S; THIH 2010) - pubmed citation

Linking in vitro survival and in vivo fitness of clinical Leishmania donovani strains (Vanaerschot M, Maes I, Ouakad M, Adaui V, Maes L, De Doncker S, Rijal S, Chappuis F, Dujardin JC, Decuypere; PLoS One 2010) - pubmed citation

Detection of Leptomonas sp. parasites in clinical isolates of Kala-azar patients from India. (Srivastava P, Prajapati VK, Vanaerschot M, Van der Auwera G, Dujardin JC, Sundar S; Infect Genet Evol 2010) - pubmed citation

Collaborative actions in anti-trypanosomatid chemotherapy with partners from disease endemic areas. (Dujardin JC, Pacanowska DG, Croft SL, Olesen OF, Späth GF; Trends in Parasitol 2010) -
pubmed citation

Towards an unbiased metabolic profiling of protozoan parasites: optimisation of Leishmania sampling protocol for HILIC-LC analysis. ('t Kindt R, Jankevics A, Scheltema RA, Zheng L, Watson DG, Dujardin JC, Breitling R, Coombs GH, Decuypere S; Anal Bioanal Chem 2010) - pubmed citation

Metabolomics to unveil and understand phenotypic diversity among pathogen populations. (t'Kindt R, Scheltema RA, Jankevics A, Brunker K, Rijal S, Dujardin JC, Breitling R, Watson DG, Coombs GH, Decuypere S; PLoS Negl Trop Dis 2010) - pubmed citation

A simple data reduction method for high resolution LC/MS data in metabolomics. (Scheltema RA, Decuypere S, Dujardin JC, Watson DG, Jansen RC, Breitling R; Bioanalysis 2009) - pubmed citation

 

Peer-reviewed review papers

(Post-) genomic approaches to tackle drug resistance in Leishmania. (Berg M, Mannaert A, Vanaerschot M, Van der Auwera G, Dujardin JC - Parasitol 2013) - in press
 
LC-MS metabolomics from study design to data-analysis - using a versatile pathogen as a test case. (Berg M, Vanaerschot M, Jankevics A, Cuypers B, Breitling R, Dujardin JC. Comp Struct Biotech J 2013) - open access citation
 
Drug-resistant microorganisms with a higher fitness - can medicines boost pathogens? (Vanaerschot M, Decuypere S, Berg M, Roy S, Dujardin JC; Critical Reviews in Microbiology 2012) - pubmed citation
 
Adaptive mechanisms in pathogens: universal aneuploidy in Leishmania. (Mannaert A, Downing T, Imamura H, Dujardin JC; Trends in Parasitol 2012) - pubmed citation
 
Combination therapy for visceral leishmaniasis. (van Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, Boelaert M; Lancet Infect Dis 2010) - pubmed citation

Structure, dynamics and function of Leishmania genome: resolving the puzzle of infection, genetics and evolution? (Dujardin; Infect Genet Evol 2009) - pubmed citation

The potential of metabolomics for Leishmania research in the post-genomics era. (Scheltema and Decuypere; Parasitology 2009) - pubmed citation

 

 

Conference abstracts

 
1. Metabolomics for global characterisation of phenotypic diversity in Leishmania populations. (Decuypere, WorldLeish 4 2009) - download pdf
2. Kaladrug-R: towards improved monitoring of drug resistance and treatment response in Indian VL. (Dujardin, WorldLeish 4 2009) - download pdf
3. Treatment failure and drug resistance in visceral and tegumentary leishmaniasis: How many roads must a parasite walk down? (Dujardin, WorldLeish 4 2009) - download PDF
4. Antimonial-resistant Leishmania donovani: increasing the clinical predictive value of the current in vitro susceptibility test. (Vanaerschot, WorldLeish 4 2009) - download PDF
5. Understanding drug resistance in natural Leishmania donovani populations: Are we underestimating the legacy left by antimonials to Kala-azar control? (Decuypere, WorldLeish 4 2009) - download PDF
6. Metabolomics to reveal phenotypic diversity in natural Leishmania populations. (Decuypere, British Society of Parasitology Autumn Symposium on Parasite metabolomics 2009) - download pdf
7. Visceral leishmaniasis: modelling & control. (Stauch, Design and Analysis of Infectious Disease Studies 2009)
8. Stability of microsatellite marker mets in Leishmania. (Stark, German Society of Parasitology 2010)
9. Patterns of population genomic variation in Leishmania donovani. (Downing, British Society of Parasitology Spring Meeting 2010) - download pdf
10. Whole comparative genome sequencing reveals several levels of genomic diversity among Leishmania donovani strains in Indian subcontinent. (Imamura, British Society of Parasitology Spring Meeting 2010) - download pdf
11. KALADRUG-R: towards improved monitoring of drug resistance and treatment response in Indian VL. (Dujardin, 12th International Conference on Parasitology) - download PDF
12. An LC-MS based metabolomics platform for Leishmania: development and evaluation. (t'Kindt, 12th International Conference on Parasitology) - download PDF
13. Whole comparative genome sequencing reveals several levels of genomic diversity among Leishmania donovani strains in Indian subcontinent. (Imamura, 12th International Conference on Parasitology) - download PDF
14. Linking in vitro and in vivo fitness of SSG-sensitive and SSG-resistant Leishmania donovani from Nepal to the complexity of survival. (Vanaerschot, 12th International Conference on Parasitology)
15. Drug susceptibility of Indian field isolates of L. donovani and development of experimental resistance towards Miltefosine and Paromomycin. (Bhandari, FP7 conference on NTD)
16. Microsatellite typing of Leishmania donovani from the Indian subcontinent reveals a homogenous population structure. (Stark, FP7 conference on NTD)
17. How does antimonial resistance affect the survival skills of Leishmania donovani? (Vanaerschot, FP7 conference on NTD)
18. Modelling visceral leishmaniasis transmission and control. (Stauch, FP7 conference on NTD)
19. Challenges for the implementation of new tools to monitor treatment outcome in Miltefosine-treated Kala-azar patients in India and Nepal. (Ostyn, FP7 conference on NTD)
20. Molecular and biochemical characterization of resistant Leishmania donovani isolates. (Mukhopadhyay, FP7 conference on NTD)
21. Experimental induction of Paromomycin resistance in an antimony-resistant Nepalese strain of L. donovani. (Inocencio, FP7 conference on NTD)
22. Treatment of Indian visceral leishmaniasis with Miltefosine – 10 years later. (Prajapati, FP7 conference on NTD)
23. The utility and efficacy of Miltefosine as a 1st line therapy for Kala-azar in Nepal. (Bhattarai, FP7 conference on NTD)
24. Inherent paromomycin susceptibility and induction of resistance of SSG-sensitive and SSG-resistant Nepalese Leishmania donovani strains. (Lonchamp, FP7 conference on NTD)
25. Natural susceptibility of Leishmania donovani isolates from Indian subcontinent towards Miltefosine and impact of SSG resistance background on development of Miltefosine resistance. (Kulshrestha, FP7 conference on NTD)
26. The genome of Leishmania donovani from clinically isolated parasites in India and Nepal. (Imamura, FP7 conference on NTD)
27. Microsatellite typing of Leishmania donovani from the Indian subcontinent reveals a homogenous population structure. (Stark, Annual meeting of the Consortium of Gene-Diagnostics 2010)
28. Exploring genome-wide variation in Leishmania donovani. (Downing, 10th International conference on molecular epidemiology and evolutionary genetics on infectious diseases 2010) - download PDF
29. A global study of whole genome and metabolome diversity in natural Leishmania donovani populations. (Decuypere, 10th International conference on molecular epidemiology and evolutionary genetics on infectious diseases 2010) - download PDF
30. Leishmania as a paradigm for exploring the impact of genome diversity on metabolome variation. (Berg, Trypanosomatidés 2011: du terrain au laboratoire 2011) - download PDF
31. In the shadow of the genome: a challenging journey to the diversity of Leishmania donovani. (Dujardin, Belgian Society of Parasitology 2011)
32. Visceral leishmaniasis in the Indian subcontinent: modeling epidemiology and control. (Duerr, ISID-NTD 2011) - download PDF
33. Leishmania as a paradigm for exploring the impact of genome diversity on metabolome variation. (Berg, Metabomeeting 2011, Metabolic Profiling Forum 2011) - download PDF
34. Viscerale Leishmaniose auf dem Indischen Subcontinent: Mathematische Modellierung von Epidemiologie und Bekämpfung. (Stauch, GMDS & DGEpi 2011) - download PDF
35. In the shadow of the genome: a challenging journey to the diversity of Leishmania donovani. (Dujardin, Leishmania genomics 2011)
36. Leishmania as a paradigm for exploring the impact of genome diversity on metabolome variation. (Berg, Leishmania genomics 2011) - download PDF
37. Application of next genome sequencing technologies to parasite diversity studies. (Berriman, Leishmania genomics 2011)
38. New networks for detecting drug resistance: Visceral Leishmaniasis in the Indian subcontinent. (Dujardin, Expert meeting on diagnosis and detection of antimicrobial resistance in developing countries 2011)
39. In the shadow of the genome: a challenging journey to diversity in Leishmania donovani. (Imamura, COST action SEQAHEAD 2011) - download PDF
40. Structural genome variation in natural populations of Leishmania donovani through high-throughput sequencing. (Imamura, Belgium Society of Protozoology 2012)
41. Could our medicines boost pathogens? Increased fitness of antimony-resistant Leishmania donovani (Vanaerschot, BSP Spring Meeting 2012) - download PDF
42. Efficacy of Miltefosine in the treatment of visceral leishmaniasis in the Indian sub-continent: the current status. (Dujardin, BSP Spring Meeting 2012) - download PDF
43. Genetic markers for SSG-resistance in Leishmania donovani and SSG-treatment failure in visceral leishmaniasis patients of the Indian subcontinent (Vanaerschot, BSP Spring Meeting 2012) - download PDF
44. Leishmania as a paradigm to explore the impact of genome diversity on metabolome variation (Berg, BSP Spring Meeting 2012) - download PDF
45. Structural variation and genome diversity in natural populations of Leishmania donovani. (Imamura, BSP Spring Meeting 2012) - download PDF
46. Episomal gene amplification and copy number variation in natural populations of Leishmania donovani (Mannaert, BSP Spring Meeting 2012) - download PDF
47. Population structure and adaptive evolution of a recent Leishmania epidemic. (Downing, BSP Spring Meeting 2012)
48. Real-time genome evolution in natural populations of Leishmania donovani across two successive drug eras (Dujardin, Infectious Disease and Genomics Conference, Cambridge, 2012) - download PDF
49. Challenges for detecting genetic variation of Leishmania donovani in natural populations and among experimentally induced drug-resistant lines. (Imamura, Infectious Disease and Genomics Conference, Cambridge, 2012) - download PDF
50. Episomal gene amplifciation in natural populations of Leishmania donovani. (Mannaert, Infectious Disease and Genomics Conference, Cambridge, 2012) - download PDF
51. Antimony resistance in Leishmania donovani: a metabolomics study on the promastigote life stage. (Berg, Belgian Society of Biochemistry and Molecular Biology 2012) - download PDF
52. Antimony resistance in Leishmania donovani: a metabolomics study on the promastigote life stage. (Berg, Trypanosomatidés: du terrain au laboratoire 2012) - download PDF
53. The curious case of antimony resistant Leishmania donovani - the first naturally emerged drug resistant pathogen with a higher fitness (Vanaerschot, SSG conference Calcutta India 2012) - download PDF
54. Drug resistance in Leishmania: lessons for successful adaptation (Dujardin, Pathogen's survival strategies: from fundamentals to field, ITM colloquium 2012)- download PDF
55. Drug-resistant Leishmania donovani with a higher fitness - could our medicines boost pathogens? (Vanaerschot, Pathogen's survival strategies: from fundamentals to field, ITM colloquium 2012) - download PDF
56. Episomal gene amplification in natural populations of Leishmania donovani (Mannaert, Pathogen's survival strategies: from fundamentals to field, ITM colloquium 2012) - download PDF
57. Antimony resistance in Leishmania donovani: an integrated omics study on the promastigote life stage (Berg, Pathogen's survival strategies: from fundamentals to field, ITM colloquium 2012) - download PDF
58. Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia (Osyn and Boelaert, Health Systems and Control of Negelected Diseases in Asia, 55th ITM colloquium, Bangalore, India 2013) - download PDF
59. Lessons learnt from Kaladrug-R: New tools for monitoring drug resistance and treatment response in visceral leishmaniasis in the Indian subcontinetn (Ostyn, Health Systems and Control of Negelected Diseases in Asia, 55th ITM colloquium, Bangalore, India 2013) - download PDF   

Search